ライフサイエンスコーパス: C. guilliermondii

1 sis; 16 (100%), 4 (95.5%), and 4 (98.9%) for C. guilliermondii.

2 r more of the echinocandins, most (68%) were C. guilliermondii.

3 e not significantly different from those for C. guilliermondii.

4 ogy and antifungal susceptibility profile of C. guilliermondii.

5 is to 100% for C. krusei, C. lusitaniae, and C. guilliermondii.

6 ranged from 0% for C. lusitaniae to 100% for C. guilliermondii.

7 or C. glabrata to 100% for C. lusitaniae and C. guilliermondii.

8 .0), 1 (92.7)/-, and 1 (100.0)/2 (100.0) for C. guilliermondii.

9 0.12; for C. lusitaniae, 0.03 and 0.007; for C. guilliermondii, 0.12 and 0.03; and for C. kefyr, 0.06

10 3/0.06, 99.7; C. krusei, 0.12/0.5, 99.0; and C. guilliermondii, 0.5/1, 94.4.

11 ; C. kefyr, 0.06/0.06; C. parapsilosis, 1/2; C. guilliermondii, 0.5/1; C. lusitaniae, 0.12/0.25; othe

12 ), 8 (95.0), 0.5 (97.5), and 0.25 (98.0) for C. guilliermondii; 0.25 (98.9), 0.03 (98.0), 0.12 (97.5)

13 67 isolates of C. lusitaniae, 48 isolates of C. guilliermondii, 10 isolates of C. famata, 10 isolates

14 mong the emerging fluconazole-R species were C. guilliermondii (11.4% R), C. inconspicua (53.2% R), C

15 mutant strain), 25 of C. parapsilosis, 19 of C. guilliermondii, 12 of C. tropicalis (2 mutant strains

16 ng methods demonstrated that 19 strains were C. guilliermondii, 14 were C. parapsilosis, 5 were C. lu

17 abrata (2 fluconazole-resistant isolates), 5 C. guilliermondii (2 fluconazole-resistant isolates), 10

18 olates were C. parapsilosis, 6 isolates were C. guilliermondii, 2 isolates were C. rugosa, and 1 isol

19 97%; C. glabrata, 93%; C. parapsilosis, 85%; C. guilliermondii, 83%; and C. lusitaniae, 50%.

20 for C. krusei, 100%, 100%, and 100%; and for C. guilliermondii, 90.2%, 95.1%, and 100%.

21 C. guilliermondii, a species that exhibits reduced susce

22 C. guilliermondii and C. rugosa were most prominent in L

23 . lusitaniae, 0.5 (98.9) and 0.25 (98.3) for C. guilliermondii, and 0.25 (100.0) and 0.015 (100.0) fo

24 labrata, 12% C. tropicalis, 3% C. krusei, 1% C. guilliermondii, and 2% other Candida spp.

25 2.0% were due to C. krusei, 0.7% were due to C. guilliermondii, and 5.8% were due to Candida spp.

26 picalis, 270 C. krusei, 99 C. lusitaniae, 88 C. guilliermondii, and 61 C. kefyr isolates) were obtain

27 5 isolates of C. lusitaniae, 177 isolates of C. guilliermondii, and 93 isolates of C. kefyr were obta

28 % for C. krusei to 100% for C. parapsilosis, C. guilliermondii, and C. lusitaniae.

29 Clinical data related to the infection with C. guilliermondii are sparse.

30 Others (C. lusitaniae, C. guilliermondii) are haploid, and their mating produce

31 rved in strains of C. krusei, C. lusitaniae, C. guilliermondii, C. inconspicua, and C. sake.

32 is, C. dubliniensis, C. famata, C. glabrata, C. guilliermondii, C. kefyr, C. krusei, C. lusitaniae, C

33 to detect seven additional Candida species (C. guilliermondii, C. kefyr, C. lambica, C. lusitaniae,

34 lates include Candida krusei, C. lusitaniae, C. guilliermondii, C. kefyr, C. rugosa, C. lipolytica, C

35 to 100% for C. tropicalis, C. parapsilosis, C. guilliermondii, C. krusei, and C. lusitaniae.

36 , C. parapsilosis, C. krusei, C. lusitaniae, C. guilliermondii, C. lipolytica, C. rugosa, and C. zeyl

37 nce over time was seen with C. parapsilosis, C. guilliermondii, C. lusitaniae, C. sake, and C. pellic

38 ion and antifungal susceptibilities of 1,029 C. guilliermondii clinical isolates collected from 127 m

39 tion, with some species (e.g., C. rugosa and C. guilliermondii) demonstrating reduced susceptibilitie

40 ighlights the high mortality associated with C. guilliermondii fungemia in immunocompromised patients

41 lity was directly or partially attributed to C. guilliermondii fungemia in only four cases (19.0%).

42 A majority (76.2%) of cases of C. guilliermondii fungemia treated at our tertiary care

43 ent approaches, and outcomes associated with C. guilliermondii fungemia.

44 C. guilliermondii grows poorly under anaerobic condition

45 tropicalis in 9%, C. parapsilosis in 3%, and C. guilliermondii in 3%.

46 r, extensive environmental sampling revealed C. guilliermondii in an anaerobic holding jar in the cli

47 A molecular evaluation of the C. guilliermondii isolates confirmed a common source for

48 the observation that a notable proportion of C. guilliermondii isolates exhibit non-wild-type profile

49 antifungal susceptibility testing (AST) for C. guilliermondii isolates submitted to a reference labo

50 increasing azole resistance over time among C. guilliermondii isolates tested from 2001 to 2003.

51 C. krusei (n = 143), C. lusitaniae (n = 54), C. guilliermondii (n = 39), C. pelliculosa (n = 17), C.

52 C. parapsilosis (n = 39), C. krusei (n = 5), C. guilliermondii (n = 6), and C. lusitaniae (n = 2).

53 . krusei (n = 5), C. lusitaniae (n = 2), and C. guilliermondii (n = 6).

54 15 with low confidence between C. famata and C. guilliermondii or C. parapsilosis, displaying only 56

55 C. guilliermondii represented 1.4% of the 75,761 isolate

56 C. tropicalis, C. krusei, C. lusitaniae, and C. guilliermondii) simultaneously with very high specifi

57 Of 132 bloodstream isolates of C. guilliermondii tested against caspofungin, most were

58 oriconazole was more active in vitro against C. guilliermondii than fluconazole (91% susceptible; ran

59 usceptibility of 132 bloodstream isolates of C. guilliermondii to caspofungin.

60 ocandins may be used for empiric therapy for C. guilliermondii until the results of AST are available

61 lbicans, C. parapsilosis, C. tropicalis, and C. guilliermondii were all highly susceptible to both fl

62 One hundred twelve blood culture isolates of C. guilliermondii were identified, and clinical data wer

63 ml), and C. parapsilosis, C. lusitaniae, and C. guilliermondii were the least susceptible (MIC(90), 0

64 rapsilosis and variants of C. lusitaniae and C. guilliermondii were the most resistant, demonstrating